论文部分内容阅读
[目的]了解曲妥珠单抗治疗乳腺癌疗效相关基因的研究现状及生物学信息。[方法]检索Embase、Medline/Pubmed及BIOSIS Preview数据库,收集曲妥珠单抗治疗乳腺癌疗效相关基因的文献,分析其发表年代、国家、期刊、作者及研究机构分布等;对最终获得的117个基因进行生物信息学分析,分析曲妥珠单抗相关基因及产物相互作用、分类,并分析关键基因及瓶颈基因。[结果]81篇文献符合要求,共涉及117个基因,所涉及的基因及其产物处于相互联系的复杂网络之中。Bcl-2、EGFR、PIK3CA、PTEN、AKT1和ErbB2同时为Hub基因和Bottleneck基因。[结论]曲妥珠单抗治疗乳腺癌疗效相关基因的研究处于蓬勃发展时期,将会有更多的基因得到关注。
[Objective] To understand the current status and biological information of trastuzumab-resistant breast cancer-related genes. [Methods] The databases of Embase, Medline / Pubmed and BIOSIS Preview were searched, and the literature about trastuzumab treatment of breast cancer related genes was collected, and the publication date, countries, periodicals, authors and research institutes were analyzed. Bioinformatics analysis of genes, trastuzumab-related genes and product interaction, classification, and analysis of key genes and bottleneck genes. [Results] 81 literatures met the requirement, involving a total of 117 genes, the involved genes and their products are in a complex network of interconnectedness. Bcl-2, EGFR, PIK3CA, PTEN, AKT1 and ErbB2 are both Hub and Bottleneck genes. [Conclusion] The study of trastuzumab in the treatment of breast cancer efficacy-related genes is in a period of vigorous development, and more genes will be noticed.